‘If you could hallucinate a protein’: Profluent snags $35M for generative AI models

A small startup in Berkeley, CA, wants to help create the next wave of custom enzymes for gene editing systems with the help of generative AI.

To get there, Profluent reeled in another $35 million in funding, added the former head of product at OpenAI to its board and brought in a chief business officer with BD experience at Editas, Tome and Vor.

Spark Capital led the new financing, disclosed Thursday morning. Existing investors Insight Partners and Air Street Capital returned, and angel investors like Google DeepMind chief scientist Jeff Dean also took part in the round, which builds onto the $9 million the company emerged with in January 2023.

The AI protein designer will initially direct its machine-learning efforts toward CRISPR. It doesn’t have an internal pipeline but rather seeks to pair up with CRISPR leaders and other biotechs to help them make new treatments. Click here to view original post

Click Here to Publish/Feature Your Company or Product News with Biotech Networks